PIPELINE

Self Photos / Files - timeline_en1

 


 

IMC-001 

Our vaccination technology has already been successfully validated by immunogenicity examination and viral challenge studies in mouse and non-human primate models. In this pipeline, we have developed a bivalent PD-1 based DNA vaccine, ICVAX, that encode for a soluble PD-1 domain fused to two chimeric HIV antigens. As a DNA vaccine, ICVAX can be repeatedly used to boost anti-HIV immune responses without issues of pre-existing immunity against vaccine vectors. We have recently completed preclincial GLP toxicity studies to domonstrate its safety. This product is currently at the pre-IND stage.

 

IMC-002 

Based on our PD-1-based DNA vaccine platform, a COVID-19 DNA vaccine for SARS-CoV-2, namely ICCOV, has been constructed. Compared to non-targeting vaccines, pre-clinical tests in animal models demonstrate that ICCOV not only triggers a high level of neutralizing antibody response against multiple SARS-CoV-2 variants, but also induces a potent polyfunctional cytotoxic CD8+ T cell immune responses. More importantly, the effiacy of this vaccine against SARS-CoV-2 infection has been validated in mouse models. In collaboration with HKU, the first-in-human clinical trial of ICCOV has recently started. We are also conducting R&D on the booster vaccination strategy and the next generation ICCOV vaccine targeting SARS-CoV-2 variants.

 

IMC-003

Preclinical studies show that the IMC-003 vaccine, encoding a PD-1-linked tumour-associated antigen, provides effective control against established mesothelioma in combination with an immune checkpoint inhibitor in animal models.

 

IMC-004

IMC-004 is an antibody against a unique PD-1 isoform. Preclinical studies show that it has potential therapeutic effects against inflammatory-related diseases, including cancers. We are currently conducting drug candidate optimisation. In addition, the efficacy of IMC-004 to treat liver and colorectal cancers is being evaluated in preclinical animal models.

 

IMC-005

We are currently developing novel needleless injection systems for DNA vaccination, aiming to improve DNA vaccine efficiency and to minimise the invasiveness of electroporaion.